Without a rigorous discussion of the pros and cons of QbD, its tremendous benefits will be lost.
Lynn Torbeck
Advertisement
Lynn Torbeck is a statistician at Torbeck and Assoc.
Articles by Lynn Torbeck
Advertisement
Latest Updated Articles
QbD: Convincing the SkepticsMay 1st 2009
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
3
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5